December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Assessment of Visual Function in Mucolipidosis IV Using ERG, VEP and TAC
Author Affiliations & Notes
  • RC Caruso
    Ophthalmic Genetics and Visual Function Branch
    NEI NIH Bethesda MD
  • P Lopez
    Ophthalmic Genetics and Visual Function Branch
    NEI NIH Bethesda MD
  • LA Ayres
    Ophthalmic Genetics and Visual Function Branch
    NEI NIH Bethesda MD
  • JA Smith
    Division of Epidemiology and Clinical Research
    NEI NIH Bethesda MD
  • R Schiffmann
    Developmental and Metabolic Neurology Branch NINDS NIH Bethesda MD
  • Footnotes
    Commercial Relationships   R.C. Caruso, None; P. Lopez, None; L.A. Ayres, None; J.A. Smith, None; R. Schiffmann, None.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 1197. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      RC Caruso, P Lopez, LA Ayres, JA Smith, R Schiffmann; Assessment of Visual Function in Mucolipidosis IV Using ERG, VEP and TAC . Invest. Ophthalmol. Vis. Sci. 2002;43(13):1197.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Mucolipidosis type IV (ML-IV) is an autosomal recessive neurodegenerative lysosomal storage disease due to mutations in the gene encoding mucolipin 1. It causes a progressive degeneration of the retina and visual pathways. The objective of this study was to measure the degree of visual loss in patients with ML-IV. Electroretinography (ERG), visual evoked potentials (VEP), and visual acuity measurements with Teller Acuity Cards (TAC) were used for this purpose. Method: To date, 6 patients with ML-IV have been evaluated (4 female, 2 male, from 2 to 24 years of age). TAC measurements and VEP recordings were performed while awake, and ERGs were recorded under anesthesia with propofol and nitrous oxide. ERGs and VEPs were elicited by Ganzfeld flash stimuli and recorded following standard ISCEV procedures. The half-life of these variables as a function of age was calculated. Results: (1) ERG. In the youngest two patients (ages 2 and 4), cone responses, flicker responses, and the a-wave of mixed rod and cone ("maximal") responses were normal. However, the b-wave of rod responses and "maximal" responses already showed a reduction in amplitude. This gave the "maximal" responses a "negative" configuration. ERG amplitude declined rapidly as a function of age, and in the oldest patient all responses were non-recordable ("extinguished") with conventional averaging. Their half lives were 2.72, 3.45, 3.03, 3.66, and 3.70 years for rod response, "maximal" response a-wave, "maximal" response b-wave, cone, and flicker responses, respectively. (2) VEP. Similarly, flash VEP amplitude (N2-P2) was normal in the younger patients and declined to noise levels in the oldest subject (half-life: 4.75 years). VEP (P2) implicit time was delayed in all but one 4 year-old patient. (3) TAC. Acuity measurements could only be obtained in the 3 younger patients; acuity ranged between 20/80 and 20/100. The 3 older patients were unable to fixate and thus could not perform a preferential looking task. Conclusion: Retinal degeneration in ML-IV is present very early in life; the site of the initial abnormality is either at, or proximal to, the photoreceptor terminals (in bipolar or Muller cells), resulting in a reduced ERG b-wave amplitude. Soon thereafter, additional photoreceptor degeneration causes further reduction of all ERG components. VEP abnormalities and acuity loss are probably due to degeneration of both the retina and visual pathways. Clinical and genetic heterogeneity may modify these findings.

Keywords: 395 electroretinography: clinical • 393 electrophysiology: clinical • 562 retinal degenerations: hereditary 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×